Hyperlink (09989) issued an announcement that Shenzhen Haipuri Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “Company”)...
Zhitong Finance App News, Haipuri (09989) issued an announcement. Shenzhen Haipuri Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “Company”) invested in various 2023 accounts receivable, inventory, goodwill, development expenses, fixed assets and long-term equity within the scope of consolidated statements in accordance with the “Shenzhen Stock Exchange Listed Company Self-Regulatory Guidelines No. 1 - Business Handling”, “Corporate Accounting Standards” and the relevant accounting policies of the company in the process of preparing the 2023 financial statements in order to truly and accurately reflect the company's assets and financial situation Impairment tests, and based on the impairment test results, impairment provisions were calculated accordingly for assets showing signs of impairment.
The company's asset projects for impairment in 2023 mainly provide a total of RMB 1 billion for depreciation of accounts receivable, other accounts receivable, inventory, goodwill, development expenses, fixed assets, and long-term equity investments.